April 17, 2013 ·
Leave a comment
Industry Insights from Paul Meade, M.Sc, MPH
Allison Murphy and I had the pleasure of participating in the MSL Society’s inaugural global conference and gala in Philadelphia earlier this month. At Thought Leader Select, we always enjoy the opportunity to meet some of our great colleagues in medical affairs in the pharmaceutical, biotechnology, and device industries, but this event proved to be really special.
Since joining our company last year, Allison has continued to make a real impact in the medical affairs community. After serving much of the last decade in Eli Lilly’s medical affairs division in support of the company’s endocrinology portfolio, Allison has brought a wealth of medical affairs expertise to Thought Leader Select. This expertise has continued to evolve, even as a consultant, through her membership and advisory board participation with the MSL Society, a dynamic group that we are proud to support as a company.
Dr. Samuel Dyer, the founder and head of the MSL Society, approached us a few months ago, asking for help with the burgeoning organization’s first global event. As a veteran of the industry myself, I have participated in many events through the years, as a participant, speaker, and sponsor. I must admit that I was more than a little skeptical about another conference/event series emerging in a space with ... read more »
October 11, 2012 ·
Leave a comment
Thought Leader Select is pleased to announce that Allison Murphy, an executive with nearly two decades of experience working in healthcare and biopharmaceuticals, has joined the company’s team of consultants dedicated to optimizing industry collaborations with medical experts.
Murphy comes to Thought Leader Select with a track record of success in clinical work at leading medical centers of excellence, as well as sales and medical science liaison roles at Eli Lilly and Company. A 1993 graduate of Villanova University with a degree in nursing, Murphy entered clinical practice in a role leading pediatric oncology nurse teams at New York University Lagone Medical Center, followed by a stint working as a nurse coordinator in pediatric endocrinology at Columbia Presbyterian Medical Center, also in New York.
During her time at Columbia Presbyterian, Ms. Murphy managed a practice that grew from 300 to over 2000 weekly patient visits and served as study coordinator for multiple National Institutes of Health-sponsored protocols and several phase IV clinical trial collaborations with the pharmaceutical industry.
In 2001, Murphy began an 11-year run at Eli Lilly, first working as a sales specialist on behalf of the company’s portfolio of products aimed at growth disorders to help both pediatric and adult endocrinologists. Murphy ... read more »
May 2, 2012 ·
Leave a comment
By Brian Castle and Kristen Smithwick
At Thought Leader Select, we have the privilege of working with a group of people who are always mindful of our company’s place in the big world of healthcare. We view our mission as a simple one, and that is to go about our work in ways that will always ultimately promote better patient care and public health outcomes.
We collaborate, through a strategic approach, with a variety of partner companies in the healthcare space—companies developing and commercializing pharmaceuticals, biotech treatments, medical devices, and diagnostics—as well as thousands of thought leaders, key advisors, and medical centers of excellence across more than 18 therapeutic areas covering over 50 diseases and conditions that affect millions of people around the world.
This week, we are proud to launch a new expression of our company’s mission and what we see as our responsibility to our partners across healthcare and the patients we all serve. We are proud of our team’s heritage in multiple areas of healthcare—our people have led industry teams working in brand and product commercialization, predictive medicine, and strategic planning, and they have also performed critical research work and delivered clinical care to patients alongside leading physicians in many of the top medical centers on multiple continents.
On our new Our Mission and Responsibility page, you’ll see a ... read more »
April 26, 2012 ·
Leave a comment
April 26, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of an inter-disciplinary infectious disease engagement with a top 10 global biopharmaceutical company.
The biopharmaceutical company, part of a select group of global leaders in drug development for the treatment of infectious diseases, approached Thought Leader Select for support with its development pipeline across the Canadian market. To meet the combined strategic needs of the company’s emerging pipeline in treating conditions like HIV and Hepatitis-C, Thought Leader Select will deploy its in-house research group for a multi-disciplinary assessment of the key opinion leader community in infectious diseases.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following areas:
For the first wave of the assessment, the Thought Leader Select research group will identify 50 physicians appropriate for compliant engagement in support of drug development for infectious diseases, across multiple Canadian provinces.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought leaders, ... read more »
April 18, 2012 ·
Leave a comment
April 18, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a urology engagement with a top 20 global pharmaceutical company.
The pharmaceutical company, a global leader in drug development for urological conditions, approached Thought Leader Select for support with its existing portfolio of medicines, as well as new drugs in its development pipeline across the Canadian market. To meet the combined strategic needs of the company’s existing portfolio as well as its emerging pipeline, Thought Leader Select will deploy its in-house research group for a two-part assessment of the key opinion leader community in urology.
For the first wave of the assessment, the Thought Leader Select research group will validate the skills and experience of the urology specialists that currently comprise the company’s KOL roster. In addition, Thought Leader Select will identify new physicians appropriate for the panel, bringing the total roster to 40 thought leaders across multiple Canadian provinces.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as ... read more »
April 12, 2012 ·
Leave a comment
New press release out today from the offices of Thought Leader Select:
April 12, 2012 (CHAPEL HILL, NC)—Thought Leader Select, a North Carolina-based consulting firm supporting the healthcare industry, is pleased to announce the hiring of Jason Bell as its newest sales executive for the American market.
Bell comes to Thought Leader Select with a solid track record of experience within the biopharmaceutical industry, working as a field hospital representative in support of critical new drug launches in multiple therapeutic areas and disease states, for companies including Allergan, Capellon Pharmaceuticals, and Auriga Pharmaceuticals. In addition to his in-the-field experience and perspective on collaborating with key opinion leaders in medicine to promote effective new treatments, Bell also brings experience gleaned from his time at Clinsys Alterna, a contract research organization (CRO). In his business development role at Clinsys Alterna, Jason consulted with biopharmaceutical industry executives to deliver customized solutions in support of phase I-IV clinical trials.
Jason Bell is a 1997 graduate of California University of Pennsylvania, with a degree in psychology.
“I’m already enjoying my work, speaking with clients and prospective clients about their needs for medical marketing and medical science outreach to health care professionals,” stated Bell. “This company is a great match for my experience and the skills I developed in pharma, CROs, and talent management organizations serving life science ... read more »
March 27, 2012 ·
Leave a comment
Industry Insights from Kristen Smithwick
Albeit a bit late, the U. S. Centers for Medicare and Medicaid Services (CMS) issued a proposed rule on the Patient Protection & Affordable Care Act’s Physician Payments Sunshine Provision (also known as the “Sunshine Act”) to implement it as law.
CMS invited comments on the proposed rule through mid-February 2012, and a recent webcast, sponsored by PharmaLive’s Pharmalot, featured key facts and summaries of comments on the proposed rule. Working for a provider of research and consulting to the biopharmaceutical, medical device, and diagnostics industries on relationships with physicians and other health care providers, I enjoyed the opportunity to join the webcast, led by experts from Buchanan Ingersoll & Rooney, P.C., and am eager to share some of my key takeaways.
As mentioned in previous Thought Leader Select Blog posts, the Sunshine Act, as with many laws and regulations, is full of unintended consequences – some positive and some negative. Lance K. Stell, medical ethics teacher at Davidson College and Carolinas Medical Center, reports in his USA Today op-ed piece that the “Sunshine Act will cost far more than the $224 million estimated for just the first year of compliance” and that “the biggest cost will be the valuable, socially useful physician-industry collaborations that simply won’t occur.” Of course, the idea of ... read more »